|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E586. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thrift AP: The epidemic of oesophageal
carcinoma: Where are we now? Cancer Epidemiol. 41:88–95. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tachimori Y, Ozawa S, Numasaki H, Ishihara
R, Matsubara H, Muro K, Oyama T, Toh Y, Udagawa H, Uno T, et al:
Comprehensive registry of esophageal cancer in Japan, 2010.
Esophagus. 14:189–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuwano H, Nishimura Y, Oyama T, Kato H,
Kitagawa Y, Kusano M, Shimada H, Takiuchi H, Toh Y, Doki Y, et al:
Guidelines for diagnosis and treatment of carcinoma of the
esophagus April 2012 edited by the Japan Esophageal Society.
Esophagus. 12:1–30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wiedemann M and Trueb B: Characterization
of a novel protein (FGFRL1) from human cartilage related to FGF
receptors. Genomics. 69:275–279. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stauber DJ, DiGabriele AD and Hendrickson
WA: Structural interactions of fibroblast growth factor receptor
with its ligands. Proc Natl Acad Sci USA. 97:49–54. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Trueb B: Biology of FGFRL1, the fifth
fibroblast growth factor receptor. Cell Mol Life Sci. 68:951–964.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gerber SD, Steinberg F, Beyeler M,
Villiger PM and Trueb B: The murine Fgfrl1 receptor is essential
for the development of the metanephric kidney. Dev Biol.
335:106–119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gerber SD, Amann R, Wyder S and Trueb B:
Comparison of the gene expression profiles from normal and Fgfrl1
deficient mouse kidneys reveals downstream targets of Fgfrl1
signaling. PLoS One. 7:e334572012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baertschi S, Zhuang L and Trueb B: Mice
with a targeted disruption of the Fgfrl1 gene die at birth due to
alterations in the diaphragm. FEBS J. 274:6241–6253. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Amann R, Wyder S, Slavotinek AM and Trueb
B: The FgfrL1 receptor is required for development of slow muscle
fibers. Dev Biol. 394:228–241. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsuchiya S, Fujiwara T, Sato F, Shimada Y,
Tanaka E, Sakai Y, Shimizu K and Tsujimoto G: MicroRNA-210
regulates cancer cell proliferation through targeting fibroblast
growth factor receptor-like 1 (FGFRL1). J Biol Chem. 286:420–428.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shimada Y, Okumura T, Nagata T, Hashimoto
I, Sawada S, Yoshida T, Fukuoka J, Shimizu K and Tsukada K:
Expression analysis of fibroblast growth factor receptor-like 1
(FGFRL1) in esophageal squamous cell carcinoma. Esophagus.
11:48–53. 2014. View Article : Google Scholar
|
|
15
|
Shimada Y, Okumura T, Takei Y, Watanabe K,
Nagata T, Hori T, Tsuchiya S, Tsukada K and Shimizu K: Role of
fibroblast growth factor receptors in esophageal squamous cell
carcinoma. Esophagus. 13:30–41. 2016. View Article : Google Scholar
|
|
16
|
Zuo J, Wen M, Lei M, Peng X, Yang X and
Liu Z: MiR-210 links hypoxia with cell proliferation regulation in
human Laryngocarcinoma cancer. J Cell Biochem. 116:1039–1049. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schild C and Trueb B: Aberrant expression
of FGFRL1, a novel FGF receptor, in ovarian tumors. Int J Mol Med.
16:1169–1173. 2005.PubMed/NCBI
|
|
18
|
Donnard E, Asprino PF, Correa BR, Bettoni
F, Koyama FC, Navarro FC, Perez RO, Mariadason J, Sieber OM,
Strausberg RL, et al: Mutational analysis of genes coding for cell
surface proteins in colorectal cancer cell lines reveal novel
altered pathways, druggable mutations and mutated epitopes for
targeted therapy. Oncotarget. 5:9199–9213. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shimada Y, Imamura M, Wagata T, Yamaguchi
N and Tobe T: Characterization of 21 newly established esophageal
cancer cell lines. Cancer. 69:277–284. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pulukuri SM and Rao JS: Matrix
metalloproteinase-1 promotes prostate tumor growth and metastasis.
Int J Oncol. 32:757–765. 2008.PubMed/NCBI
|
|
21
|
Tassi E, McDonnell K, Gibby KA, Tilan JU,
Kim SE, Kodack DP, Schmidt MO, Sharif GM, Wilcox CS, Welch WJ, et
al: Impact of fibroblast growth factor-binding protein-1 expression
on angiogenesis and wound healing. Am J Pathol. 179:2220–2232.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bugyi B and Carlier MF: Control of actin
filament treadmilling in cell motility. Annu Rev Biophys.
39:449–470. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Abuharbeid S, Czubayko F and Aigner A: The
fibroblast growth factor-binding protein FGF-BP. Int J Biochem Cell
Biol. 38:1463–1468. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamashita K, Mori M, Kataoka A, Inoue H
and Sugimachi K: The clinical significance of MMP-1 expression in
oesophageal carcinoma. Br J Cancer. 84:276–282. 2001. View Article : Google Scholar : PubMed/NCBI
|
